Hubei Goto Biopharm Group Co., Ltd. Class A

Hubei Goto Biopharm Group Co., Ltd. Class A

SSZSE:300966
23.32
CNY
-0.48
(-2.02%)
-0.89EPS
2.96BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Hubei Goto Biopharm Group Co., Ltd. Class A carries a market capitalization of 2.96B, placing it among publicly traded companies globally. Its enterprise value stands at 4.29B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.96B
Enterprise Value4.29B

Share Statistics

As of September 30, 2026, Hubei Goto Biopharm Group Co., Ltd. Class A has 115.28M shares outstanding.

Shares Outstanding115.28M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 4.34, and the price-to-book ratio stands at 3.82.

PS Ratio4.34
PB Ratio3.82
P/TBV Ratio4.10

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 6.45 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 4.29B versus a market cap of 2.96B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales6.45

Financial Position

As of September 30, 2026, Hubei Goto Biopharm Group Co., Ltd. Class A maintains a current ratio of 1.04, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 159.83, indicating elevated leverage, while an interest coverage ratio of -2.09 demonstrates limited ability to service its debt obligations.

Current Ratio1.04
Quick Ratio0.12
Debt / Equity159.83
Debt / EBITDA-12.28
Interest Coverage-2.09

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Hubei Goto Biopharm Group Co., Ltd. Class A posted a negative return on equity (ROE) of -10.65, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.05, reflecting losses generated across the asset base. The company generates approximately 745,475.79 in revenue per employee across its workforce of 893.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.21 indicates how many times Hubei Goto Biopharm Group Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-10.65
Return on Assets (ROA)-3.05
Revenue Per Employee745,475.79
Employee Count893.00
Inventory Turnover1.21

Taxes

CNY

Over the twelve months ended September 30, 2026, Hubei Goto Biopharm Group Co., Ltd. Class A recorded an income tax benefit of -15.05M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -115.03M and -89.70M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-15.05M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Hubei Goto Biopharm Group Co., Ltd. Class A's stock has gained approximately 1.17% over the past 52 weeks. The 50-day moving average sits at 24.17, while the 200-day moving average is 24.22.

52-Week Price Change1.17%
50-Day Moving Average24.17
200-Day Moving Average24.22

Income Statement

CNY

Over the twelve months ended September 30, 2026, Hubei Goto Biopharm Group Co., Ltd. Class A generated 665.71M in revenue and converted that into -89.70M in net income, yielding earnings per share of -0.89. EBITDA reached -110.93M, while operating income came in at -48.25M.

Revenue665.71M
Gross Profit75.25M
Operating Income-48.25M
Pretax Income-115.03M
Net Income-89.70M
EBITDA-110.93M
EBIT-110.93M
Earnings Per Share (EPS)-0.89

Balance Sheet

CNY

As of September 30, 2026, Hubei Goto Biopharm Group Co., Ltd. Class A holds 108.43M in cash and equivalents against 1.36B in total debt, resulting in a net debt position of 1.14B. Total book value stands at 775.71M, with working capital of 39.22M providing operational flexibility.

Cash & Cash Equivalents108.43M
Total Debt1.36B
Net Debt1.14B
Equity (Book Value)775.71M
Book Value Per Share6.73
Working Capital39.22M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-105.08M

Margins

Over the twelve months ended September 30, 2026, Hubei Goto Biopharm Group Co., Ltd. Class A posted a gross margin of 11.30, reflecting its pricing power and cost economics. The operating margin of -7.25 and net profit margin of -13.47 provide insight into operational efficiency.

Gross Margin11.30
Operating Margin-7.25
Pretax Margin-17.28
Profit Margin-13.47
EBITDA Margin-16.66

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Hubei Goto Biopharm Group Co., Ltd. Class A paid dividends of 0.27 per share. The dividend payout ratio of -27.05 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -0.09, meaning Hubei Goto Biopharm Group Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dividend Per Share0.27
Payout Ratio-27.05
Shareholder Yield-0.09

Scores

As of September 30, 2026, Hubei Goto Biopharm Group Co., Ltd. Class A has an Altman Z-Score of 1.12, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.12